Headlines from the Proactive UK newsroom.
IQ-AI (LON:IQAI) has received FDA clearance to market its StoneChecker Software in the US. IQ-AI said it was delighted with the decision.
Synairgen (LON:SNG) is to present biomarker data from the first part of its ongoing Phase II trial of its inhaled interferon beta therapy for COPD at a major European conference this month. Synairgen’s treatment is designed to bolster COPD sufferers’ defences against viral infections such as colds and flu.
Itaconix (LON:ITX) has been rated one of "The Top 50 Companies to Disrupt the World" by Biofuels Digest, the world's most widely-read daily publication on the bioeconomy.
Sareum (LON:SAR), another UK biotech, meanwhile will present details of how one of its discoveries significantly reduces tumour growth in disease models of many cancers next month in Boston. In pre-clinical work, Sareum’s treatment promoted an anti-tumour effect by activating the local immune system to attack cancer cells.